MBX Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
MBX$56.33+4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2025 and 2024
BALANCE SHEETS
(in thousands, except share and per share amounts)
| Years ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $75,289 | $49,351 |
| Marketable securities | 298,416 | 212,798 |
| Prepaid expenses and other current assets | 7,834 | 5,137 |
| Total current assets | 381,539 | 267,286 |
| Property and equipment, net | 2,735 | 1,080 |
| Right-of-use assets | 487 | 119 |
| Other assets | 383 | 50 |
| Total assets | $385,144 | $268,535 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $2,977 | $5,335 |
| Accrued expenses | 12,346 | 5,545 |
| Operating lease liability, current | 172 | 171 |
| Total current liabilities | 15,495 | 11,051 |
| Share repurchase liability | 2 | 42 |
| Operating lease liability, net of current | 424 | — |
| Total liabilities | 15,921 | 11,093 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity (deficit) | ||
| Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized and zero issued and outstanding as of December 31, 2025 and December 31, 2024 | — | — |
| Common stock, $0.0001 par value, 500,000,000 shares authorized and 44,927,953 issued and outstanding as of December 31, 2025 and 500,000,000 shares authorized and 33,421,525 issued and outstanding as of December 31, 2024 | 6 | 5 |
| Additional paid-in-capital | 593,407 | 394,887 |
| Accumulated deficit | (224,476) | (137,505) |
| Accumulated other comprehensive income | 286 | 55 |
| Total stockholders’ equity | 369,223 | 257,442 |
| Total liabilities and stockholders’ equity | $385,144 | $268,535 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.